Intravenous iron treatment in hemodialysis patients improves the response to recombinant
human erythropoietin (rHuEPO) and facilitates achievement of targets for hemoglobin and …

Iron supplementation is an important aspect of treatment for hemodialysis patients, with most
administration by an intravenous route. As with any drug, decisions as to treatment are most …

Background Intravenous iron is widely used to control anemia in dialysis patients and limits
costs related to erythropoiesis-stimulating agents (ESA). Current guidelines do not clearly …

Background Intravenous low molecular weight iron dextran and iron sucrose have been
used for correction of iron deficiency for many years and have been shown to improve …

Background: Intravenous (IV) iron supplementation is a standard maintenance treatment for
hemodialysis (HD) patients, but the optimum dosing regimen is unknown. Methods …

Hemodialysis patients require parenteral iron to replenish/maintain sufficient iron stores and
optimize erythropoietin (EPO) use. Two parenteral iron preparations are available in the UK …

End-stage renal disease results in anemia caused by shortened erythrocyte survival,
erythropoietin deficiency, hepcidin-mediated impairment of intestinal absorption and iron …

Background. Iron deficiency is common in haemodialysis patients and adequate
supplementation by the oral or parenteral route has been limited by drug side-effects …

Aim: iv iron therapy is more effective in maintaining adequate iron status in haemodialysis
(HD) patients than oral iron therapy (OIT). However, data on lower doses of iv iron therapy …

In this issue of Kidney International, the Dialysis Outcomes and Practice Patterns Study
reports that hemodialysis patients with monthly intravenous iron supplementation of 300 …